Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BIO103
- Development stage
- Preclinical
- Lead developer
- Boostimmune
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
BIO103 is an investigational antibody-drug conjugate (ADC) developed by Boostimmune. It consists of a monoclonal antibody targeting an undisclosed oncofetal antigen—a protein typically expressed during fetal development and selectively found on specific cancer cells in adults—conjugated to a topoisomerase I (TOP1) inhibitor payload. In preclinical studies, BIO103 demonstrated significant anti-tumor efficacy with a single administration in xenograft mouse models of human small cell lung cancer (SCLC) and patient-derived liver cancer. Non-GLP toxicity studies in non-human primates have confirmed its safety profile, supporting its potential as a first-in-class therapeutic for solid tumors.
- Other names
- BIO 103BIO103BIO-103
02
Targets
TOP1 (DNA Topoisomerase I)
Beyond the preview
Go deeper on BIO103.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BIO103.